NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Some women may be unaware they're living with risks for heart disease, kidney disease and metabolic conditions like diabetes, which drive risk for cardiovascular disease. The interplay among these ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

Millions of women may be unknowingly living with risk factors for heart, kidney and metabolic disease—interconnected ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI ...

The Royal Danish Embassy in Thailand, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), organised ...